Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Revenue (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Revenue for 2 consecutive years, with $347808.0 as the latest value for Q2 2023.

  • Quarterly Revenue rose 2460.99% to $347808.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $347808.0 through Mar 2024, down 15.84% year-over-year, with the annual reading at $486559.0 for FY2022, 3130.37% up from the prior year.
  • Revenue hit $347808.0 in Q2 2023 for Pasithea Therapeutics, up from -$59646.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $347808.0 in Q2 2023 to a low of -$59646.0 in Q1 2023.